$TLRY

Tilray Brands reports record US$915.5M revenue in Fiscal 2026

Tilray Brands reported record fiscal 2026 revenue of US$915.5M, up 11% from US$821.3M, driven by cannabis, beverage, distribution and wellness. Beverage net revenue rose 6% to US$254.0M, with Q4 beverage revenue up 61% to US$105M. Adjusted EBITDA increased to US$61.1M. Tilray completed a £33M BrewDog acquisition in March. It forecasts fiscal 2027 adjusted EBITDA of US$68M to US$75M.

Original reporting
Published Jul 29, 2026, 12:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 3:02 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tilray Brands reports record US$915.5M revenue in Fiscal 2026 — source image
Decision brief

The 30-second read

$TLRYBullishMed
01

Why it matters

The key tradable inputs are the reported fiscal 2026 revenue/EBITDA and the stated fiscal 2027 adjusted EBITDA outlook, which can shift expectations for profitability and growth trajectory post-acquisition.

02

Market read

New financial datapoints plus explicit fiscal 2027 adjusted EBITDA guidance create a near-term expectation reset for Tilray’s profitability and growth narrative.

03

What to watch

The article cites fuel surcharges adjustment and “stabilised” BrewDog, but does not quantify integration costs, cash flow impact, or longer-term margin sustainability beyond the EBITDA range.

Relevance 7/10Novelty 7/10Timing: ahead of fiscal 2027 execution, with guidance for adjusted EBITDA ($68M-$75M) disclosed now

Background

Tilray Brands says fiscal 2026 results were driven by growth across cannabis, beverage, distribution, and wellness, and highlights BrewDog’s contribution after a March acquisition.

Company-level read

Ticker impact

$TLRYBullishMedium confidence
Context

Tilray reports fiscal 2026 revenue of $915.5M (+11% YoY) and raises fiscal 2027 adjusted EBITDA guidance to $68M-$75M.

Expected impact

Moderately positive bias for the next earnings/guidance reaction window, assuming the market rewards EBITDA growth and beverage stabilization.

Evidence & confidence

The article includes new, specific financial results (revenue, EBITDA, gross margin) plus explicit fiscal 2027 adjusted EBITDA range, which can drive re-rating versus prior expectations.

Market effects

Supports the broader cannabis-adjacent and beverage platform narrative that M&A can stabilize profitability and improve margins.

UK and Ireland beverage footprint expansion via BrewDog may matter for regional beverage/craft beer sentiment, but the article is company-specific.

Reinforces Tilray’s global beverage platform strategy, potentially influencing investor perception of cross-border integration success.

Counterpoint

BrewDog restructuring (pub closures and workforce reduction) may mask underlying demand softness, so EBITDA guidance could be sensitive to execution and cost normalization.

Key entities

  • Tilray Brands

    Reports record fiscal 2026 revenue and provides fiscal 2027 adjusted EBITDA guidance; acquisition of BrewDog is cited as strengthening its beverage platform.

  • BrewDog

    UK brewing operations and brand portfolio acquired for £33M; article notes pub closures and workforce reduction as part of restructuring.

  • Irwin D. Simon

    Chairman and CEO who comments on beverage platform strategy and disciplined execution.

Related articles

$CURLFHighAI 9/10

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

Curaleaf has made an unsolicited bid for Aurora Cannabis, offering a 45% premium. Aurora has not accepted the deal. Tilray Brands and Canopy Growth are also engaging in consolidation. Aurora recently acquired Safari Flower, while Canopy bought MTL Cannabis. Tilray is diversifying into alcohol and CBD. Investors should consider risks of consolidation strategies.

$TLRYMed

Tilray Posted Record Fiscal 2026 Revenue -- Why Isn't the Stock Rallying?

Tilray Brands reported record fiscal 2026 revenue of $915 million, up 11%, and adjusted EBITDA of $61.1 million, also up 11%. Adjusted net income nearly doubled to $12.2 million, but missed analyst estimates. GAAP net loss was $49.6 million. Management expects fiscal 2027 adjusted EBITDA of $68M-$75M. Cannabis sales represent 29% of total revenue.

$CURLFHighAI 8/10

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

Curaleaf (CURLF) has made an unsolicited bid for Aurora Cannabis (ACB), offering a 45% premium. Aurora's response was noncommittal. Canopy Growth (CGC) and Tilray Brands (TLRY) are also consolidating, with Tilray expanding into alcohol and CBD. Investors may benefit from acquisitions, but risks include integration challenges and leverage.

$TLRYMed

Tilray Brands (TLRY) Is Up 5.7% After Narrower Loss, ESOP Shelf Filing and M&A Signal

Tilray Brands reported Q4 sales of US$281.71 million and full-year sales of US$915.45 million for the year ended May 31, 2026, with a substantially smaller net loss than the prior year. The company also filed a US$47.69 million shelf registration for 11,355,231 common shares tied to its ESOP. Management said at-the-market equity proceeds may fund acquisitions, including deals like BrewDog.

$TLRYMed

Tilray Brands Q4 Earnings Call Highlights

Tilray Brands (NASDAQ: TLRY) reported fiscal 2026 results on its Q4 earnings call. Net loss narrowed to $105.2M ($1.09/share) from about $2.2B in fiscal 2025. Adjusted net income rose 87% to $12.2M. Cannabis and distribution revenue grew, BrewDog added beverage revenue, and Tilray guided adjusted EBITDA of $68M to $75M for fiscal 2027.